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Human T-lymphotropic virus type 1 (HTLV-1) -associated
myelopathy/tropical spastic paraparesis (HAM/TSP) is a
chronic neuroinflammatory disease. Since the disease
course of HAM/TSP varies among patients, there is a dire
need for biomarkers capable of predicting the rate of dis-
ease progression for earlier detection of high-risk patients.
However, there have been no studies to date that have
compared the prognostic values of multiple potential bio-
markers for HAM/TSP. Peripheral blood and cerebrosp-
inal fluid (CSF) samples from HAM/TSP patients and
HTLV-1-infected control subjects were obtained and
tested for several potential biomarkers, including chemo-
kines and other cytokines, and 8 optimal candidates were
selected based on receiver operating characteristic (ROC)
analysis. Next, we evaluated the relationship between these
candidates and the rate of disease progression in HAM/
TSP patients, beginning with a Training Set of 30 patients
and proceeding to a Test Set of 23 patients. We defined
“deteriorating HAM/TSP” as distinctly worsening function
(≥ 3 grades on Osame’s Motor Disability Score (OMDS))
over 4 y and “stable HAM/TSP” as unchanged or only
slightly worsened function (1 grade on OMDS) over 4 y,
and we compared the levels of the candidate biomarkers
in patients divided into these 2 groups. The CSF levels of
chemokine (C-X-C motif) ligand 10 (CXCL10), neopterin
and the CSF cell count were well-correlated with disease
progression, better even than HTLV-1 proviral load in
PBMCs. Importantly, these results were cross-validated
using the Test Set. Therefore, the CSF levels of CXCL10
and neopterin represent the most viable candidates for
HAM/TSP prognostic biomarkers.
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